Foundation medicine is a molecular information company developing clinical diagnostic tests that facilitates personalized cancer therapies. read more

EMPLOYEE PARTICIPANTS: 52

TOTAL RATINGS: 467

CEO: Dan Malarek

HR or Marketing? Claim Your Free Employer Account

Dan Malarek Foundation Medicine CEO Rating

Foundation Medicine's CEO, Dan Malarek, has 41 employee ratings and a score of 68/100, placing them in the Top 50% of similar size companies on Comparably with 501-1,000 Employees and Bottom 40% of other companies in Boston.

Last updated months ago.

Where This Score Ranks Foundation Medicine's CEO Rating

TOP
50%
In the Top 50% of 1832 Similar Sized Companies on Comparably
BOTTOM
40%
In the Bottom 40% of 270 Nearby Companies in Boston
2nd
2nd place versus 2 competitors rated on Comparably

Sep

Oct

Mar

Sep

Jul

C+68 / 100

Jan

Foundation Medicine CEO Dan Malarek Bio

Dan Malarek is Chief Executive Officer at Foundation Medicine. Prior to joining Foundation Medicine in 2023, he held several key positions within Roche Diagnostics. Most recently, Malarek worked as the Global Head of Marketing & Customer Insights, based in Rotkreuz, Switzerland, moving to that role after serving as the General Manager for Roche Diagnostics Norway for four years.

Who Ranks Foundation Medicine's CEO Rating the Highest?

Experience - Over 10 Years 90/100

Gender - Female 81/100

Ethnicity - Caucasian 72/100

Who Ranks Foundation Medicine's CEO Rating the Lowest?

Tenure - 2 to 5 Years 67/100

Experience - 1 to 3 Years 70/100

Foundation Medicine CEO Dan Malarek At a Glance

The CEO score provides an understanding of how employees feel about the CEO’s leadership style and effectiveness at Foundation Medicine.

Based on 41 ratings, Dan Malarek ranks right below Flatiron Health's CEO, Carolyn Starrett.

Foundation Medicine's CEO is highly regarded by employees with Over 10 Years experience, Female employees, and Caucasian employees. However, employees who have been at the company 2 to 5 Years and employees with 1 to 3 Years experience have a less favorable view of the CEO and believe there is room for improvement. Overall, the CEO score has remained stable over the last 90 days.